DENDREON PHARMACEUTICALS LLC.
History
| Year | Detail |
|---|---|
| 1992 | Edgar Engleman and Samuel Strober established Activated Cell Therapy in Mountain View, California, U.S., during their Stanford School of Medicine research. |
| 1993 | Activated Cell Therapy opened its first research and development (R&D) facility. |
| 1995 | The company developed the Antigen Delivery Cassette, an active cellular immunotherapy platform. |
| 1997 | Activated Cell Therapy changes its name to Dendreon Pharmaceuticals LLC. |
| 2006 | Dendreon submitted the Biologics License Application (BLA), an active cellular immunotherapy for cancer, to the FDA. |
| 2010 | Dendreon received FDA approval for sipuleucel-T (PROVENGE), the first FDA-approved immunotherapy developed from a patient's immune cells. |
| 2011 | The FDA has approved PROVENGE manufacturing sites in Seal Beach, California, and Union City, Georgia. |
| 2015 | Valeant Pharmaceuticals International has acquired Dendreon for $495 million. |
| 2017 | Dendreon resumed its operations as a standalone company after Sanpower Group's acquisition for $819.9 million. |
BCC Research Beacon 